The effects of inhaled budesonide on the duration of respiratory support in preterm infants with high-risk of bronchopulmonary dysplasia:a randomized controlled trial
The effects of inhaled budesonide on the duration of respiratory support in preterm infants with high-risk of bronchopulmonary dysplasia:a randomized controlled trial
Objective To study the effects of inhaled budesonide during 7-14 d after birth on the duration of respiratory support in preterm infants with high-risk of bronchopulmonary dysplasia(BPD).Methods From March 2021 to December 2023,preterm infants admitted to our hospital and still needed non-invasive respiratory support at 7-14 d of age were randomly assigned into two groups.The budesonide group inhaled budesonide(0.5 mg,once every 12 h)until withdrawal of respiratory support and the control group inhaled saline alone.The duration of respiratory support,effectiveness and safety indicators were compared between the two groups.Results A total of 87 cases were enrolled,including 44 in the budesonide group and 43 in the control group.The total duration of respiratory support[(36.6±15.4)d vs.(43.0±13.4)d,P=0.043]and the duration of atmospheric oxygen inhalation[(20.1±8.7)d vs.(24.2±8.3)d,P=0.028]in the budesonide group were shorter than the control group(P＜0.05).No significant differences existed between the two groups in the following items:duration of positive pressure or high flow respiratory support,the overall incidence and different grades of BPD,usage of short-course low-dose dexamethasone therapy,hyperglycemia,gastrointestinal bleeding,late-onset sepsis,pulmonary hemorrhage,air leak syndrome,stage Ⅱ-Ⅲ necrotizing enterocolitis,stage Ⅱ-Ⅳintraventricular hemorrhage,retinopathy of prematurity requiring treatment at initial screening,the volume of erythrocyte suspension infusion,haemodynamically significant patent ductus arteriosus at discharge and the length of hospital stay(all P＞0.05).Conclusions Inhaled budesonide during 7-14 d of life may shorten the duration of respiratory support in preterm infants with high-risk for BPD,without increasing the incidences of adverse effects and poor outcomes.However,budesonide does not effectively reduce the overall incidence and the severity of BPD.
维普
万方数据